Taking into consideration the AIS burden and the role of VK in vascular diseases, we evaluated the prognostic value of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 polymorphisms for 5-year mortality after AIS, together with established clinical and imaging predictors (age, NIHSS, lesion volume, comorbidities), in patients not treated with VK antagonists. This evidence concerns the gene VKORC1 and androgen insensitivity syndrome.